title: Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
abstract: BACKGROUND
  Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxicity and efficacy and allow dose escalation to depend on a pre-specified efficacy/toxicity tradeoff in a phase I-II design. Several phase I-II trial designs have been discussed in the literature; while these model-based designs are attractive in their performance, they are potentially vulnerable to model misspecification.
  
  
  METHODS
  Phase I-II designs often rely on copula models to specify the joint distribution of toxicity and efficacy, which include an additional correlation parameter that can be difficult to estimate. We compare and contrast three models for the joint probability of toxicity and efficacy, including two copula models that have been proposed for use in phase I-II clinical trials and a simple model that assumes the two outcomes are independent. We evaluate the performance of the various models through simulation both when the models are correct and under model misspecification.
  
  
  RESULTS
  Both models exhibited similar performance, as measured by the probability of correctly identifying the optimal dose and the number of subjects treated at the optimal dose, regardless of whether the data were generated from the correct or incorrect copula, even when there is substantial correlation between the two outcomes. Similar results were observed for a simple model that assumes independence, even in the presence of strong correlation. Further simulation results indicate that estimating the correlation parameter in copula models is difficult with the sample sizes used in Phase I-II clinical trials.
  
  
  CONCLUSIONS
  Our simulation results indicate that the operating characteristics of phase I-II clinical trials are robust to misspecification of the copula model but that a simple model that assumes independence performs just as well due to difficulty in estimating the copula model correlation parameters from binary data.
authors.forename: Kristen
authors.initials: K
authors.lastname: Cunanan
authors.affiliation: Division of Biostatistics, School of Public Health, University of Minnesota, A460 Mayo Building, MMC 303, 420 Delaware St, SE, 55455 Minneapolis, MN, USA. koopm007@umn.edu.
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Koopmeiners
mesh_terms: D000465:Algorithms; D001499:Bayes Theorem; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020714:Maximum Tolerated Dose; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design
references.citation: Stat Med. 1995 Jun 15;14(11):1149-61
references.pmid: 7667557
references.citation: Control Clin Trials. 2002 Jun;23(3):240-56
references.pmid: 12057877
references.citation: Stat Med. 2006 Jul 30;25(14):2365-83
references.pmid: 16220478
references.citation: Clin Trials. 2008;5(5):465-77
references.pmid: 18827039
references.citation: Biometrics. 2006 Sep;62(3):777-84
references.pmid: 16984320
references.citation: Biometrics. 1989 Sep;45(3):925-37
references.pmid: 2790129
references.citation: Biometrics. 2004 Sep;60(3):684-93
references.pmid: 15339291
references.citation: Biometrics. 1990 Mar;46(1):33-48
references.pmid: 2350571